Amicus Therapeutics is a biotechnology company that is breaking ground in the therapeutic world. They are a global company based out of Cranbury, New Jersey but also have locations all over the world. They are currently operating in Germany, Italy, Spain, The Netherlands, and France as well. One aspect of the business that Amicus Therapeutics prides themselves on is that they are primarily patient-oriented, and only do operate around the fact that what they are doing is always in the best interest of the patient and their family.
Amicus Therapeutics is a business driven company that uses advancements in technology to power their practice. They specialize in the research and development of a clinical trial program for rare human genetic diseases. After establishing a clinical trial for the disease that is being studied, Amicus Therapeutics will then move forward with developing a treatment plan using the wide range of technology that is available to them (SeekingAlpha).
Some examples of existing programs that they are currently offering treatment for include; Fabry disease, Epidermolysis Bullosa (EB), and Pompe disease, all of which are genetic disorders that are extremely rare and difficult to find treatment options. Amicus Therapeutics puts their patients first and do whatever it takes to provide their them with quality care and fair treatment. When researching a particular disease, Amicus Therapeutics starts at the root of the disease and comes up with a pre-clinical plan, after it is determined what the condition entails, they then are able to move it into the clinical trial period, which is where their extensive scientific knowledge and technology advancements help to provide not only answers but also relief to the people suffering from these rare conditions. For more information or if you are seeking medical help for a rare genetic disorder go to https://www.google.com/finance?cid=706165